Clareo Health | Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
50–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Mild AD Subjects meeting National Institute of Neurological Disorders and Stroke - Alzheimer's Disease Related Disorders Association(NINCDS-ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Forth Edition, Text Revision (DSM-IV-TR) criteria
Mini-Mental State Exam (MMSE) Score between 20 \& 26 (inclusive)
CSF consistent with AD pathology
Screening brain MRI - normal - commensurate with age or demonstrate atrophy consistent with AD diagnosis (dx); reveal no more than mild white matter disease; up to 2 lacunar infarcts acceptable except in anterior thalamus, genu of internal capsule or basal forebrain; reveal no cortical infarcts; reveal no more than 4 microbleeds; reveal no focal asymmetric lobar atrophy or other findings suggesting primary cause of dementia is attributed to a cause other than AD; reveal no macrohemorrhages (\>10 mm)
Subjects must have reliable study partners
Men and Women of Non Child Bearing Potentia (WONCBP), ages 50-90 years
You may not be if
Subjects with any other medical condition other than mild AD that could explain subjects' memory or cognitive deficits
Subjects diagnosed with moderate or severe AD per DSM-IV criteria
Subjects with a history (hx) of stroke
Subjects with a hx of GI illnesses
Subjects with Vitamin B12 or folate deficiency
Subjects with any unstable cardiovascular (CV), pulmonary, Gastrointestinal (GI) or hepatic disease within 30 days prior to screening
Subjects with active liver dx or history of hepatic intolerance
Subjects with a Geriatric Depression Scale score of ≥ 6 at screening
Subjects treated for or have had a diagnosis of schizophrenia
Subjects treated for or have had a diagnosis of bipolar disease within 3 years prior to screening
Subjects with a history of generalized peripheral neuropathy
